NCT05742217View on ClinicalTrials.gov

A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases

RecruitingOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

May 26, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Relapse Multiple MyelomaRefractory Multiple Myeloma
Trial Locations (1)

47014

RECRUITING

IRST, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC)

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY